The European Commission has approved an agreement with the US company Novavax to purchase up to 200 million COVID-19 vaccines. The first deliveries may start in the fourth quarter of this year.
Under the deal, EU countries will be able to purchase up to 100 million doses of Novavax vaccine, as well as 100 million additional doses by 2023, when the vaccine is approved by the EU drug market regulator, the Commission said.
“As new variants of the coronavirus are spreading across Europe around the world, this new deal with a company that is already successfully testing its vaccine against these variants provides additional protection for our population,” said President Ursula von der Leyen, chairwoman of the press release. The European Commission.
“This is another key step towards ensuring that Europe is well prepared to deal with the COVID-19 pandemic,” the release reads.
As indicated, today’s agreement completes the extensive vaccine portfolio. Agreements with the following companies were listed here: AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, Moderna and preliminary talks with Valneva were completed.
Main photo source: PAP / Marcin Obara